Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.

Abstract: Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. The levels of Pin1 can be protein levels or nucleic acid levels.

Abstract: The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer.

Abstract: The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer.

Abstract: This invention pertains to methods of treating Pin1 associated disorders through the administration of an MSPCIT. The invention further pertains to novel compounds that are able to modulate Pin1 activity by forming a specific covalent interaction with an amino acid residue in the active site of Pin1.

Abstract: The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer.

Abstract: The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer.

Abstract: This invention pertains to methods of treating Pin1 associated disorders through the administration of inhibitors of the Pin1 isomerase activity.

Abstract: This invention relates to methods for designing specific inhbitors of Pin1/parvulin family of peptidyl-prolyl cis-trans isomerases, particularly Pin1 and Pin1-related proteins, through the use of the structure coordinates and atomic details elucidated from the crystal structures of a mutant of Pin1, R14A, and co-complexes of R14A with various inhibitors. The invention further relates to inhibitors of Pin1 and Pin1-related proteins that are useful for therapeutic treatement of various disorders, and methods of using Pin1 inhibitors in pharmaceutical compositions. The invention further relates to the crystal structures of Pin1R14A alone, and of Pin1R14A in co-complex with molecules that bind to Pin1.

Abstract: The invention is directed to modulators, e.g, inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer.

Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin 1 and the amplification of Pin 1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.

Abstract: Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.